TW202306983A - 抗ｃｄ２０抗體之放射性複合體，及放射性醫藥 - Google Patents

抗ｃｄ２０抗體之放射性複合體，及放射性醫藥 Download PDF

Info

Publication number
TW202306983A
TW202306983A TW111114988A TW111114988A TW202306983A TW 202306983 A TW202306983 A TW 202306983A TW 111114988 A TW111114988 A TW 111114988A TW 111114988 A TW111114988 A TW 111114988A TW 202306983 A TW202306983 A TW 202306983A
Authority
TW
Taiwan
Prior art keywords
antibody
complex
aforementioned
group
radioactive
Prior art date
Application number
TW111114988A
Other languages
English (en)
Chinese (zh)
Inventor
河谷稔
竹中文章
花田貴寿
殿谷豪太
武田拓也
Original Assignee
日商日本醫事物理股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日本醫事物理股份有限公司 filed Critical 日商日本醫事物理股份有限公司
Publication of TW202306983A publication Critical patent/TW202306983A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111114988A 2021-04-20 2022-04-20 抗ｃｄ２０抗體之放射性複合體，及放射性醫藥 TW202306983A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021-071320 2021-04-20
JP2021071320 2021-04-20
JP2022-030389 2022-02-28
JP2022030389 2022-02-28

Publications (1)

Publication Number Publication Date
TW202306983A true TW202306983A (zh) 2023-02-16

Family

ID=83722303

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111114988A TW202306983A (zh) 2021-04-20 2022-04-20 抗ｃｄ２０抗體之放射性複合體，及放射性醫藥

Country Status (5)

Country Link
US (1) US20240207464A1 (https=)
EP (1) EP4327831A4 (https=)
JP (1) JPWO2022224980A1 (https=)
TW (1) TW202306983A (https=)
WO (1) WO2022224980A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
RU2005122033A (ru) 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
US20050255042A1 (en) * 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
ES3058443T3 (es) 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
JP7291395B2 (ja) 2017-06-16 2023-06-15 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
BR112020012099A2 (pt) * 2017-12-18 2020-11-17 Janssen Biotech, Inc. radiomarcação de polipeptídeos
SG11202009990UA (en) * 2018-04-16 2020-11-27 Nihon Mediphysics Co Ltd Modified antibody and radioactive metal-labelled antibody
JPWO2021075546A1 (https=) * 2019-10-18 2021-04-22
IL292133A (en) * 2019-10-18 2022-06-01 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
TWI886164B (zh) 2019-10-24 2025-06-11 國立大學法人鹿兒島大學 1價ccap生成物之製造方法
JP2021071320A (ja) 2019-10-29 2021-05-06 株式会社Ｇｓユアサ Ｓｏｈ推定装置、蓄電装置及びｓｏｈ推定方法
JP7581695B2 (ja) 2020-08-07 2024-11-13 スズキ株式会社 リアコンビネーションランプの保護構造
EP4397320A1 (en) * 2021-08-31 2024-07-10 Nihon Medi-Physics Co., Ltd. Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product

Also Published As

Publication number Publication date
JPWO2022224980A1 (https=) 2022-10-27
US20240207464A1 (en) 2024-06-27
WO2022224980A1 (ja) 2022-10-27
EP4327831A1 (en) 2024-02-28
EP4327831A4 (en) 2026-02-11

Similar Documents

Publication Publication Date Title
TWI875842B (zh) 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體
JP7679326B2 (ja) Ｒｉ標識されたヒト化抗体
TW202325343A (zh) 去醣基化抗體之放射性複合體，及放射性醫藥
WO2024090488A1 (ja) 放射性医薬組成物
TW202306983A (zh) 抗ｃｄ２０抗體之放射性複合體，及放射性醫藥
CN116456992A (zh) 抗her2抗体的放射性复合物和放射性药物
US20240207463A1 (en) Radioactive complex of anti-egfr antibody, and radiopharmaceutical
TW202233247A (zh) 抗ｈｅｒ２抗體之放射性複合體及放射性醫藥
EP4480502A1 (en) Radioactive complex of anti-vegf antibody, and radiopharmaceutical
CN117769440A (zh) 抗cd20抗体的放射性复合物和放射性药物
EA050335B1 (ru) Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство
KR20230174238A (ko) 방사성 항종양제
EA051630B1 (ru) Радиоактивные комплексы анти-her2 антитела и радиофармацевтическое средство
HK40092772A (zh) 抗her2抗体的放射性复合物和放射性药物
CN117377690A (zh) 抗egfr抗体的放射性复合物和放射性药物
WO2022225006A1 (ja) β線を放出する核種で標識されたヒト化抗体
EA050695B1 (ru) Способ получения антитела, меченного радиоактивным металлом